How the FDA Regulates Dietary Supplements

Dietary supplements occupy a distinct regulatory space under federal law — one that differs fundamentally from the rules governing prescription drugs, over-the-counter medications, and food additives. The framework established by the Dietary Supplement Health and Education Act of 1994 (DSHEA) places the primary burden of safety on manufacturers, not on the FDA, before products reach store shelves. Understanding this structure matters because it shapes how enforcement actions are triggered, what label claims are permissible, and what recourse consumers and industry have when problems arise.

Definition and scope

Under 21 U.S.C. § 321(ff), a dietary supplement is defined as a product intended to supplement the diet that contains one or more of the following: a vitamin, a mineral, an herb or botanical, an amino acid, a dietary substance used to supplement the diet by increasing total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any of those ingredients. The product must be labeled as a dietary supplement and cannot be represented as a conventional food or sole item of a meal.

This definition excludes products that were previously approved as new drugs or authorized for clinical investigation before being marketed as supplements — a boundary that has generated significant regulatory disputes, particularly around ingredients like N-methyltyramine and certain synthetic compounds.

The FDA's Center for Food Safety and Applied Nutrition (CFSAN) holds primary jurisdiction over dietary supplements. The FDA overview of dietary supplement regulation confirms that the United States dietary supplement market includes more than 90,000 products as of the FDA's own published estimates.

How it works

The DSHEA framework operates on a post-market enforcement model. Manufacturers do not need FDA approval before selling a dietary supplement. Instead, the following structure governs market entry and ongoing compliance:

1. Pre-market notification for new dietary ingredients (NDIs): Any ingredient not marketed in the United States before October 15, 1994 — classified as a "new dietary ingredient" — requires the manufacturer to submit a New Dietary Ingredient notification to FDA at least 75 days before marketing (21 CFR Part 190). The notification must provide a reasonable expectation of safety.

2. Good Manufacturing Practices (GMP): Manufacturers, packagers, and distributors must comply with dietary supplement GMP regulations codified at 21 CFR Part 111. These rules cover identity, purity, strength, and composition of finished products.

3. Labeling requirements: Labels must carry a "Supplement Facts" panel, list all dietary ingredients and their quantities, and include the name and place of business of the manufacturer or distributor. Structure/function claims are permitted but must include a mandatory disclaimer stating that the FDA has not evaluated the claim and that the product is not intended to diagnose, treat, cure, or prevent any disease (21 CFR § 101.93).

4. Adverse event reporting: Since the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006, manufacturers and distributors are required to report serious adverse events to the FDA using MedWatch Form 3500A. The fda-adverse-event-reporting framework covers this obligation across product categories.

5. Post-market surveillance and enforcement: The FDA monitors the market through inspections, consumer complaints, and adverse event reports. When a product is found to be adulterated or misbranded, the agency may issue warning letters, initiate recalls, or pursue injunctive relief.

Common scenarios

Structure/function claims vs. disease claims: A manufacturer may state that a product "supports healthy immune function" (a permissible structure/function claim) but may not claim that it "prevents the flu" (a disease claim requiring drug approval). The distinction turns on whether the claim references a named disease or condition. The FDA's guidance on structure/function claims provides the analytical framework for this boundary.

New dietary ingredient disputes: A manufacturer introducing an extract not commercially available before October 1994 must file an NDI notification. The FDA may object within the 75-day review window. If the agency issues an objection letter, the manufacturer must reformulate, provide additional safety data, or withdraw the ingredient from the product.

GMP inspection findings: FDA investigators examining a supplement manufacturer may find deficiencies in identity testing — for example, a failure to confirm that an herbal ingredient matches its labeled species. This constitutes a GMP violation under 21 CFR Part 111 and can trigger a fda-enforcement-actions-and-recalls response. The fda-good-manufacturing-practices framework details the inspection standards applied.

Spiked products: The FDA regularly identifies supplements — particularly those marketed for weight loss, sexual enhancement, or athletic performance — that contain undisclosed pharmaceutical ingredients. Products containing undeclared active drug substances are classified as adulterated drugs, not dietary supplements, regardless of how they are labeled.

Decision boundaries

The central regulatory distinction lies in how dietary supplements compare to drugs and conventional foods:

The fda-food-additives-and-gras page covers how the GRAS determination pathway applies to food ingredient safety reviews — a distinct process from NDI notification.

A product crosses from supplement to drug territory when its label or promotional materials make explicit disease claims, or when it is formulated with drug ingredients at pharmaceutical doses. The FDA's dietary supplement regulation overview provides detailed guidance on category boundary analysis. For a broader map of how dietary supplements fit within FDA jurisdiction, the FDA regulatory overview establishes the full scope of the agency's authority across all product categories.